share_log

HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $10 Price Target

Benzinga ·  Sep 18, 2023 06:32

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $10 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment